BMJ  2004;328:405 (14 February), doi:10.1136/bmj.328.7436.405-b

Letter

Prevention of coronary heart disease

Data in table 2 could be shown more explicitly for better understanding

The first 100% of the full text of this article appears below.

EDITOR—The cost effectiveness study published by Marshall is difficult to understand in its technical details not only by average readers but also people with some skill in pharmacoeconomics.1

We think that the part of this study that presents the data of the average cost effectiveness (table 1 of the article) is useless because the practical implications of this study, along with the assessment of the pharmacoeconomic profile of the various drugs, rely exclusively on the findings of the incremental cost effectiveness analysis (the data presented in table 2).

Table 2 is not adequately explained by the author. For this reason, we propose a more detailed layout, in which much more information is presented and the labelling of each row is made more explicit (see bmj.com).

Andrea Messori, coordinator

andreamessori@interfree.it

Benedetta Santarlasci, researcher

Laboratorio SIFO di Farmacoeconomia, Careggi University Hospital, 50134 Florence, Italy

See table on bmj.com

Competing interests: None declared.

  1. Marshall T. Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ 2003;327: 1264-7. (29 November.)[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Coronary heart disease prevention: insights from modelling incremental cost effectiveness
Tom Marshall
BMJ 2003 327: 1264. [Abstract] [Full Text] [PDF]

Access jobs at BMJ Careers
Whats new online at Student BMJ